GlassScriptPhysician profile
Leslie H Brown
NPI 1952733651
$6,450.98
in general payments reported to CMS, 2019-2025
24 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $216 · 2022: $1,400 · 2023: $1,496 · 2024: $2,128 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,834.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,106.20 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,057.67 | 2022-2024 | |
| Lilly USA, LLC | $702.05 | 2022-2025 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $483.75 | 2023-2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $404.84 | 2021-2024 | Spravato |
| Gilead Sciences, INC. | $370.75 | 2022-2025 | |
| Genzyme Corporation | $242.05 | 2022-2025 | |
| Viiv Healthcare Company | $224.17 | 2022-2025 | Apretude |
| Sanofi-Aventis U.S. LLC | $193.48 | 2022-2023 | |
| Abbott Laboratories | $162.88 | 2025 | Freestyle Libre 3 |
| Madrigal Pharmaceuticals | $146.52 | 2025 | Rezdiffra |
| Dexcom, INC. | $142.08 | 2024 | Dexcom G7 Gss (161) |
| Novo Nordisk INC | $123.26 | 2025 | Wegovy |
| Xeris Pharmaceuticals, INC. | $121.87 | 2023 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $121.83 | 2024 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $121.80 | 2023 | Qutenza |
| Astellas Pharma US INC | $120.93 | 2024 | Veozah |
| Corcept Therapeutics | $114.55 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.53 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2023 | Lifevest |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $98.06 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.42 | 2022 | |
| Boston Scientific Corporation | $75.30 | 2023 | |
| Csl Behring | $13.99 | 2023 | Kcentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.